This goal is now achievable with tumor-targeted antibody drug conjugates (ADC) that use DNA-targeted payloads such as the DNA alkylating agent PBD (pyrrolobenzodiazepine dimer) [29] or the TOP1 inhibitors, SN-38 and deruxtecan [30] (part 5 in Figure 2). The gene discussed is TOP1; the disease is neoplasm.